ClinDatrix client AiViva Biopharma launches “A Phase 2, Multicenter, Randomized, Active-controlled Trial of the Safety and Efficacy of AIV007 by Periocular Injection in Patients with Neovascular Age-Related Macular Degeneration (nAMD).” Up to fifteen sites are anticipated.
The Experience of Big. The Advantage of Value.
- About Us
- Services
- Clinical Trial Project Management
- Clinical Trial Investigator Meetings & Event Planning
- Clinical Trial Monitoring
- Clinical Trial Medical Monitor & Medical Safety
- Clinical Trial Data Management
- Clinical Trial Biostatistics
- Medical Writing Services
- Clinical Regulatory Affairs
- Quality Assurance for Clinical Trials
- Clinical Trials Consultant
- Therapeutic Areas
- Medical Devices
- Technology
- Global Affiliates
- Contact Us
Home » News & Events » ClinDatrix Client AiViva Biopharma Launches a New Study